Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, discusses immunotherapeutic options for patients with mantle cell lymphoma (MCL) who relapse or progress on Bruton's tyrosine kinase (BTK) inhibitors. Dr Cohen first explains the promise of CAR-T cells, including brexucabtagene autoleucel, and then goes on to highlight the potential role of antibodies, antibody-drug conjugates (ADCs), and bispecifics. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
